A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown.
It is the first time that a Phase III trial of viral immunotherapy has definitively shown benefit for patients with cancer.
The trial was led in the UK by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 64 research centres worldwide, including the University of Oxford.
Researchers randomised 436 patients with aggressive, inoperable malignant melanoma to receive either an injection of the viral therapy, called Talimogene Laherparepvec, or a control immunotherapy.
Some 16.3% of the group given Talimogene Laherparepvec – known as T-VEC – showed a durable treatment response of more than six months, compared with 2.1% given the control treatment.
Some patients had a response extending past three years, a mark oncologists often use as a proxy for cure in immunotherapy.
Importantly, responses to treatment were most pronounced in patients with less advanced cancers (stage IIIB, IIIC, IVM1a) and those who had yet to receive any treatment – underlining the potential benefits of T-VEC as a first-line treatment for metastatic melanoma which cannot be surgically removed.
Patients with stage III and early stage IV melanoma treated with T-VEC – a total of 163 people – lived an average of 41 months. This compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy.
The trial was funded by the manufacturer of T-VEC, Amgen, and is published in the Journal of Clinical Oncology.
T-VEC is a modified form of herpes simplex virus type-1 which multiplies inside cancer cells and bursts them from within. It has been genetically engineered to produce a molecule called GM-CSF, which stimulates the immune system to attack and destroy the tumour.
T-VEC is one of a new wave of virus-based drugs to show benefits in cancer trials, and is now the first to do so in a major randomised, controlled Phase III trial.
The virus has been modified to remove two key genes, called ICP34.5 and ICP47, so that it can’t replicate within healthy cells. Normal cells detect and destroy T-VEC before it can cause damage – but it replicates easily in cancer cells because their infection defences are compromised by genetic errors.
UK trial leader Professor Kevin Harrington, Professor of Biological Cancer Therapies at the ICR and Honorary Consultant at The Royal Marsden, said: “There is increasing excitement over the use of viral treatments like T-VEC for cancer, because they can launch a two-pronged attack on tumours – both killing cancer cells directly and marshalling the immune system against them. And because viral treatment can target cancer cells specifically, it tends to have fewer side-effects than traditional chemotherapy or some of the other new immunotherapies.
“Our study showed that T-VEC can deliver a significant, durable benefit for people with melanoma. It is encouraging that the treatment had such a clear benefit for patients with less advanced cancers – ongoing studies are evaluating if it can become a first-line treatment for more aggressive melanomas and advanced disease.”
The Latest on: Viral immunotherapy
[google_news title=”” keyword=”Viral immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Viral immunotherapy
- IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccineon February 22, 2024 at 11:34 am
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality. LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IM ...
- Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&Don February 21, 2024 at 3:28 pm
The mpox outbreak is a memory, but Bavarian Nordic, maker of the only FDA-approved vaccine for the pathogen behind this viral infection ... A cancer vaccine is a type of immunotherapy that gets the ...
- Researchers find possible predictor of COVID-19 severityon February 21, 2024 at 7:18 am
Hence, these results inform the development of immunotherapy strategies for viral diseases." The authors hope this study on 22 patients leads to larger patient studies that verify these results, and ...
- KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officeron February 21, 2024 at 5:00 am
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of industry leader James M. Burke ...
- Oncolytic Virus Immunotherapy Market Expected to Reach USD 572.2 million by 2031, Expanding at a 21.1% CAGR | Transparency Market Research, Inc.on February 21, 2024 at 3:07 am
The two main drivers driving up the value of the oncolytic virus immunotherapy market are the rising incidence of cancer and the increase in healthcare expenditures.Wilmington, Delaware, United States ...
- Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.on February 20, 2024 at 3:00 pm
Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer, commented, “This is a moment of profound sadness for those of us who had the privilege of knowing Joseph. His ...
- Drexel Researchers Find Possible Predictor of COVID-19 Severityon February 20, 2024 at 8:40 am
Looking closely at one of the antibodies produced to fight COVID-19, researchers at Drexel University’s College of Medicine have uncovered a trait that could be used to predict severity of a COVID-19 ...
- New Trial Shows a Cure for HIV May be Possibleon February 20, 2024 at 5:59 am
A small trial that combined the anticancer drug Zolinza with an immunotherapy had a modest impact on antiviral activity in patients with HIV. Researchers are hoping better approaches can be found to ...
- Cancer Immunotherapy Stocks - Tapping Into Immune Systems For Next Generation Treatments - Financial News Mediaon February 15, 2024 at 11:56 am
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential. Pelareorep is ...
- New Approach Found to Reduce Toxicity in Immunotherapyon February 15, 2024 at 9:45 am
There are various ways to treat cancer. The gold standard has been chemotherapy for over 50-years. However, treatment with immunotherapy is quickly becoming commonplace in clinics. Immunotherapy is a ...
via Bing News